血清胃泌素释放肽前体检测对小细胞肺癌诊断及预后的临床价值

目的 探讨血清胃泌素释放肽前体(pro-GRP)对小细胞肺癌(SCLC)的诊断及预后价值.方法 选取2018年1月至2021年1月吉林大学第一医院经病理组织学确诊为肺癌的2584例患者,其中SCLC 132例,非小细胞肺癌(NSCLC)2452例.采用电化学发光免疫分析法(Roche Cobas e601)检测各组血清...

Clinical significance of pro-gastrin-releasing peptide for diagnosis and prognosis of small-cell lung cancer

Objective?To explore the clinical diagnostic and prognostic significance of pro-gastrin-releasing peptide (pro-GRP) in small-cell lung cancer (SCLC).?Methods?A total of 2 584 patients with lung cancer diagnosed pathologically in the First Hospital of Jilin University from January 2018 to January 2021 were enrolled, including 132 cases of SCLC and 2 452 cases of non-small-cell lung cancer (NSCLC). Pro-GRP levels were measured in electrochemiluminescence immunoassay by Roche Cobas e601. The levels of neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), cytokeratin fragment 19 (CYFAR21-1), squamous cell carcinoma antigen (SCC) and other tumor markers in each group were also measured simultaneously. The receiver operating characteristic curves was used to evaluate the diagnostic efficiency of each tumor marker in single and combined detection of lung cancer. The levels of Pro-GRP and NSE in serum of the 132 SCLC patients were continuously monitored to analyze the consistency of the levels of both Pro-GRP and NSE with prognosis of the patients.?Results?In SCLC patients, median levels of pro-GRP were significantly higher than those of other groups (P<0.05). The area under the ROC curve, sensitivity and specificity of pro-GRP were shown to reach 0.976, 76.6% and 99.7% respectively. Combined detection of multiple markers improved the sensitivity, specificity, positive predictive value, negative predictive value and the total effective rate, which were all higher than the results of relying on a single marker (P<0.05). Among the patients responded effectively to chemotherapy, the serum pro-GRP level after the second cycle of chemotherapy was significantly lower than baseline level (P<0.001). For the patients with relapse or progression due to drug resistance, their increase of pro-GRP level was earlier than the change of NSE.?Conclusion?Pro-GRP may be used as a new tumor marker for diagnosis, prognosis and monitoring for the effects of therapy in SCLC patients.